drugset
drugset / Trial / NCT06137482

A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

NCT06137482 ↗

Phase 1 Completed 56 enrolled Regeneron Pharmaceuticals
RandomizedSequentialQuadruple-blindTreatment

Summary

This study is researching an experimental drug called REGN13335. This is the first time that REGN13335 will be given to people. This study will enroll healthy adults. The aim of the study is to see how safe and tolerable REGN13335 is in healthy volunteers. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is present in the blood of study participants at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Timeline

Start
2023-12-06
Primary completion
2025-02-11
Completion
2025-02-11

Drugs

EvaluationDrugModalityDoseRoute
Subject REGN13335 Monoclonal antibody — Intravenous

Indications

No indication recorded.